XML 75 R64.htm IDEA: XBRL DOCUMENT v3.19.2
Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jan. 01, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares, beginning balance (in shares)     3,577,103,522    
Equity, beginning balance $ 27,670 $ 33,901 $ 26,882 $ 34,569  
Net income attributable to Merck & Co., Inc. 2,670 1,707 5,585 2,443  
Adoption of new accounting standards         $ 48
Other comprehensive income (loss), net of taxes (16) (62) 183 62  
Cash dividends declared on common stock (1,440) (1,291) (2,869) (2,592)  
Treasury stock shares purchased (1,235) (1,596) (2,325) (2,162)  
Share-based compensation plans and other 117 103 360 394  
Net income (loss) attributable to noncontrolling interests (26) 9 $ (79) 14  
Distributions attributable to noncontrolling interests   (5)   (10)  
Other changes in noncontrolling ownership interests $ (3)        
Shares, ending balance (in shares) 3,577,103,522   3,577,103,522    
Equity, ending balance $ 27,737 $ 32,766 $ 27,737 $ 32,766  
Cash dividends declared on common stock (in dollars per share) $ 0.55 $ 0.48 $ 1.10 $ 0.96  
Common Stock          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares, beginning balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000  
Equity, beginning balance $ 1,788 $ 1,788 $ 1,788 $ 1,788  
Shares, ending balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000  
Equity, ending balance $ 1,788 $ 1,788 $ 1,788 $ 1,788  
Other Paid-In Capital          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Equity, beginning balance 38,768 39,874 38,808 39,902  
Treasury stock shares purchased 1,000   1,000    
Share-based compensation plans and other (284) (133) (324) (161)  
Equity, ending balance 39,484 39,741 39,484 39,741  
Retained Earnings          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Equity, beginning balance 44,065 41,107 42,579 41,350  
Net income attributable to Merck & Co., Inc. 2,670 1,707 5,585 2,443  
Adoption of new accounting standards         322
Cash dividends declared on common stock (1,440) (1,291) (2,869) (2,592)  
Equity, ending balance 45,295 41,523 45,295 41,523  
Accumulated Other Comprehensive Loss          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Equity, beginning balance (5,346) (5,060) (5,545) (4,910)  
Adoption of new accounting standards         $ (274)
Other comprehensive income (loss), net of taxes (16) (62) 183 62  
Equity, ending balance $ (5,362) $ (5,122) $ (5,362) $ (5,122)  
Treasury Stock          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares, beginning balance (in shares) 994,000,000 885,000,000 985,000,000 880,000,000  
Equity, beginning balance $ (51,736) $ (44,041) $ (50,929) $ (43,794)  
Treasury stock shares purchased (in shares) 24,000,000 27,000,000 38,000,000 37,000,000  
Treasury stock shares purchased $ (2,235) $ (1,596) $ (3,325) $ (2,162)  
Share-based compensation plans and other (in shares) (8,000,000) (5,000,000) (13,000,000) (10,000,000)  
Share-based compensation plans and other $ 401 $ 236 $ 684 $ 555  
Shares, ending balance (in shares) 1,010,000,000 907,000,000 1,010,000,000 907,000,000  
Equity, ending balance $ (53,570) $ (45,401) $ (53,570) $ (45,401)  
Non- Controlling Interests          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Equity, beginning balance 131 233 181 233  
Net income (loss) attributable to noncontrolling interests (26) 9 (79) 14  
Distributions attributable to noncontrolling interests   (5)   (10)  
Other changes in noncontrolling ownership interests (3)        
Equity, ending balance $ 102 $ 237 $ 102 $ 237